Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinical development.

Just a few days after Biogen abandoned its tau-targeting Alzheimer's disease candidate gosuranemab, Bristol-Myers Squibb has opted into a rival drug, paying $80 million for rights to Prothena's ...

afimetoran], and Alzheimer's disease [Anti-MTBR Tau]. Now, dear Seeking Alpha readers, I want to draw your attention to the ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Bristol Myers Squibb was in a strong position in Q2 FY2024 ... in neuropsychiatry and broadening of its indications in Alzheimer's and bipolar disorder represent growth opportunities.

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Bristol Myers’ $1.5 billion restructuring initiative ... Beyond schizophrenia, BMS’ ADEPT program for Cobenfy in Alzheimer’s disease psychosis could read out in 2026. And the company plans ...

We also expect to announce multiple clinical readouts from our ongoing Phase 1 ASCENT clinical trials evaluating PRX012 for Alzheimer’s disease starting in mid-2025 and continuing throughout the year.

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE ... These drugs are also being tested for Alzheimer’s and other conditions commonly linked to obesity.